R-Zero is the first biosafety company dedicated to making the spaces we all live, learn, work, and play safer and clinically clean. Founded to help businesses protect what matters most, R-Zero's suite of thoughtfully designed, hospital-grade technologies and science-backed protocols reduces the transmission of pathogens and the diseases they cause - from the coronavirus to the common cold. R-Zero's flagship product, Arc, is a touchless, hospital-grade UV-C disinfection device, designed to be operationally and financially accessible to organizations of all shapes and sizes. BLE, LTE-M and GPS connectivity shares usage data in real-time, providing organizations with an auditable trail of all disinfection activities for the first time. Results from recent independent lab tests prove Arc's hospital-grade efficacy, successfully destroying over 99.99% of pathogens (including human coronavirus and norovirus) in a 1,000 sq ft space, in just 7 minutes.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
11/10/20	$15,000,000	Series A	Bedrock Capital DBL Partners SOSV	undisclosed
06/17/21	$41,500,000	Series B	DBL Partners John Doerr SOSV	undisclosed
02/16/23	$105,000,000	Series C	Bedrock Capital BMO Financial Group DBL Partners John Doerr Mayo Clinic Qualcomm Ventures SOSV Upfront Ventures World Innovation Lab	undisclosed